-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BMS-986415 in Cutaneous T-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMS-986415 in Cutaneous T-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BMS-986415 in Cutaneous T-Cell Lymphoma Drug Details: BMS-986415 (DF-6002) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KTX-1001 in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KTX-1001 in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.KTX-1001 in Refractory Multiple Myeloma Drug Details:KTX-1001 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KTX-1001 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KTX-1001 in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.KTX-1001 in Relapsed Multiple Myeloma Drug Details:KTX-1001 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TAK-007 in Follicular Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TAK-007 in Follicular Lymphoma Drug Details: TAK-007 is under development for the treatment of relapsed...
-
Product Insights
Multiple Myeloma (Kahler Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Multiple Myeloma Pipeline Products Market Report Overview Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. It mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain, and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery. The Multiple Myeloma Drugs in Development market research...